Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK)
HKD 13.9
(17.0%)
HKD 13.9
(17.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -104.72 Million CNY | 74.66% |
| 2022 | -413.31 Million CNY | -9.48% |
| 2021 | -378.12 Million CNY | -18.55% |
| 2020 | -318.44 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 46.5 Million CNY | 0.0% |
| 2024 Q1 | 46.5 Million CNY | 217.06% |
| 2023 FY | - CNY | 74.66% |
| 2023 Q4 | -39.72 Million CNY | 0.0% |
| 2023 Q3 | -39.72 Million CNY | -10.06% |
| 2023 Q2 | -36.09 Million CNY | 0.0% |
| 2023 Q1 | -36.09 Million CNY | 72.47% |
| 2022 Q1 | -101.84 Million CNY | 7.86% |
| 2022 Q4 | -131.08 Million CNY | 0.0% |
| 2022 FY | - CNY | -9.48% |
| 2022 Q3 | -131.08 Million CNY | -28.72% |
| 2022 Q2 | -101.84 Million CNY | 0.0% |
| 2021 Q2 | -97.2 Million CNY | 0.0% |
| 2021 FY | - CNY | -18.55% |
| 2021 Q4 | -110.52 Million CNY | 0.0% |
| 2021 Q3 | -110.52 Million CNY | -13.71% |
| 2021 Q1 | -97.2 Million CNY | 0.0% |
| 2020 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 214.789% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 121.514% |